Genexine Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.8yrs

Jüngste Management Updates

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Geschäftsführer

Genexine hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jungwon Woo	President & Director	2.8yrs	keine Daten	0% ₩ 0
Neil K. Warma	President & Director	2.5yrs	keine Daten	keine Daten
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	no data	keine Daten	5.75% ₩ 15.4b
Sung-June Hong	Executive VP	no data	keine Daten	keine Daten
Jongsoo Lee	Senior Manager of IR & PR	no data	keine Daten	keine Daten
Hyun Jin Park	EVP of Corporate Development	2.8yrs	keine Daten	keine Daten
Jong Sup Park	Chief Medical Officer	5.7yrs	keine Daten	keine Daten
Jang Hee Lee	EVP of Operations	2.8yrs	keine Daten	keine Daten
Ki Yong Kim	SVP of Bio Research Institute	2.8yrs	keine Daten	keine Daten
Chul Jun Hyun	Auditor & Director	2.8yrs	keine Daten	keine Daten
Jaehyun Choi	Head of R&D	less than a year	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: A095700Das Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jungwon Woo	President & Director	2.8yrs	keine Daten	0% ₩ 0
Neil K. Warma	President & Director	2.5yrs	keine Daten	keine Daten
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	2.8yrs	keine Daten	5.75% ₩ 15.4b
Sung-June Hong	Executive VP	2.8yrs	keine Daten	keine Daten
Chul Jun Hyun	Auditor & Director	2.8yrs	keine Daten	keine Daten
Young-Jin Kim	Chairman of BOD	2.8yrs	keine Daten	keine Daten
Keon Pai Jin	Non-Executive Director	2.8yrs	keine Daten	keine Daten
Mijung Ahn	Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Peter Laivins	Director	2.8yrs	keine Daten	keine Daten
Hyeok Jong Lee	Director	2.8yrs	keine Daten	keine Daten
Heeseop Shin	Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Munseok Gang	Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: A095700Die Vorstandsmitglieder gelten nicht als erfahren ( 2.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Genexine Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

No independent directors

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

Recent updates

New minor risk - Shareholder dilution

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

Geschäftsführer

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter